Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: ...

Boston Scientific Corporation announced the close of its acquisition of Silk Road Medical, Inc. the developer of transcarotid ...

Complete revascularization was associated with a significant reduction in the primary endpoint compared with culprit-only ...

Platelets, the small cell fragments circulating in your blood, are essential for healing injuries by clumping together to ...

The following is a summary of “Prevention of Heart Failure in Hypertension – the Role of Coronary Heart Disease Events ...

Of note, the update is endorsed by EACTS, resolving some lingering left main debate, amid lots of other revised advice.

Boston Scientific (NYSE: BSX) announced today that it completed its $1.16 billion acquisition of Silk Road Medical ...

The primary efficacy endpoint was the occurrence of a major adverse cardiovascular event (MACE) at 30 days, which was defined ...

LONDON, England—Patients ages 75 and older with STEMI and multivessel coronary disease appear to fare better if they undergo complete revascularization rather than culprit-only PCI, the EARTH-STEMI ...

分析发现，完全血运重建术组的死亡、心肌梗死或缺血驱动的血运重建术的主要复合终点事件发生率为20.8%，仅干预罪犯血管组为25.2%，完全血运重建术使主要复合终点事件风险降低22%，组间差异持续4年。

Endovascular techniques combine chemical thrombolysis and mechanical clot removal strategies and can achieve higher revascularization rates, potentially translating into clinical benefit.